• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

口服含异烟肼、利福平及吡嗪酰胺的聚（丙交酯-乙交酯）微粒对实验性结核病的化疗潜力

Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.

作者信息

Ul-Ain Qurrat, Sharma Sadhna, Khuller G K

机构信息

Department of Biochemistry, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India.

出版信息

Antimicrob Agents Chemother. 2003 Sep;47(9):3005-7. doi: 10.1128/AAC.47.9.3005-3007.2003.

DOI:10.1128/AAC.47.9.3005-3007.2003
PMID:12937014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC182631/
Abstract

Poly(lactide-co-glycolide) (PLG) microspheres (diameter, less than 3 microm) containing isoniazid, rifampin, and pyrazinamide were used in a sustained oral drug delivery system to treat murine tuberculosis. Drug levels above the MIC were observed up to 72 h in plasma and for 9 days in various organs. Relative bioavailability of encapsulated drugs was greater than that of free drugs. Chemotherapy results showed better or equivalent clearance of bacilli in the PLG-drug-administered group (weekly) than with free drugs (daily).

摘要

聚（丙交酯-乙交酯）（PLG）微球（直径小于3微米）含有异烟肼、利福平和吡嗪酰胺，被用于一种持续口服给药系统来治疗小鼠结核病。在血浆中观察到药物水平高于最低抑菌浓度（MIC）长达72小时，在各个器官中则持续9天。包封药物的相对生物利用度高于游离药物。化疗结果显示，PLG药物给药组（每周一次）对杆菌的清除效果优于或等同于游离药物给药组（每日一次）。

相似文献

1
Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampin, and pyrazinamide against experimental tuberculosis.口服含异烟肼、利福平及吡嗪酰胺的聚（丙交酯-乙交酯）微粒对实验性结核病的化疗潜力
Antimicrob Agents Chemother. 2003 Sep;47(9):3005-7. doi: 10.1128/AAC.47.9.3005-3007.2003.
2
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.用于实验性结核病的基于聚（DL-丙交酯-共-乙交酯）纳米颗粒的可吸入持续给药系统
J Antimicrob Chemother. 2003 Dec;52(6):981-6. doi: 10.1093/jac/dkg477. Epub 2003 Nov 12.
3
Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s).聚[DL-丙交酯-乙交酯]在抗结核药物持续口服给药系统开发中的作用。
Int J Pharm. 2002 Jun 4;239(1-2):37-46. doi: 10.1016/s0378-5173(02)00034-0.
4
Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.聚（DL-丙交酯-共-乙交酯）包裹的抗结核药物对小鼠诱导的结核分枝杆菌感染的治疗效果。
Antimicrob Agents Chemother. 2001 Jan;45(1):363-6. doi: 10.1128/AAC.45.1.363-366.2001.
5
Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.用包裹在聚（DL-丙交酯-共-乙交酯）微粒中的异烟肼和利福平联合治疗小鼠结核分枝杆菌感染。
J Antimicrob Chemother. 2001 Jun;47(6):829-35. doi: 10.1093/jac/47.6.829.
6
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.实验模型中基于纳米颗粒的皮下抗结核化疗
J Antimicrob Chemother. 2004 Jul;54(1):266-8. doi: 10.1093/jac/dkh260. Epub 2004 May 5.
7
Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs.纳米颗粒包裹的抗结核药物的化疗疗效
Drug Deliv. 2006 Jul-Aug;13(4):287-94. doi: 10.1080/10717540500398076.
8
Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects.基于藻酸盐的结核病口服给药系统：药代动力学与治疗效果
J Antimicrob Chemother. 2003 Apr;51(4):931-8. doi: 10.1093/jac/dkg165. Epub 2003 Mar 13.
9
Oral solid lipid nanoparticle-based antitubercular chemotherapy.基于口服固体脂质纳米粒的抗结核化疗
Tuberculosis (Edinb). 2005 Sep-Nov;85(5-6):415-20. doi: 10.1016/j.tube.2005.08.009. Epub 2005 Oct 26.
10
Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.异烟肼、利福平及吡嗪酰胺（游离组合或固定三联制剂）在间歇抗结核化疗中的生物利用度。
Monaldi Arch Chest Dis. 1993;48(3):205-9.

引用本文的文献

1
An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management.纳米技术在治疗、药物递送、诊断和疫苗研发方面的进展洞察：在结核病管理中的多维应用
Pharmaceuticals (Basel). 2023 Apr 12;16(4):581. doi: 10.3390/ph16040581.
2
Preparation and evaluation of gelatin/sodium carboxymethyl cellulose polyelectrolyte complex microparticles for controlled delivery of isoniazid.制备和评价明胶/羧甲基纤维素钠聚电解质复合微球用于异烟肼的控制释放。
AAPS PharmSciTech. 2009;10(4):1412-9. doi: 10.1208/s12249-009-9344-9. Epub 2009 Nov 24.
3
3D Multi-agent models for protein release from PLGA spherical particles with complex inner morphologies.用于从具有复杂内部形态的聚乳酸-羟基乙酸共聚物（PLGA）球形颗粒中释放蛋白质的3D多智能体模型。
Theory Biosci. 2008 Jun;127(2):95-105. doi: 10.1007/s12064-008-0041-0. Epub 2008 Apr 26.

本文引用的文献

1
Gliadin nanoparticles as carriers for the oral administration of lipophilic drugs. Relationships between bioadhesion and pharmacokinetics.麦醇溶蛋白纳米颗粒作为亲脂性药物口服给药的载体。生物黏附与药代动力学之间的关系。
Pharm Res. 2001 Nov;18(11):1521-7. doi: 10.1023/a:1013018111829.
2
Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.用包裹在聚（DL-丙交酯-共-乙交酯）微粒中的异烟肼和利福平联合治疗小鼠结核分枝杆菌感染。
J Antimicrob Chemother. 2001 Jun;47(6):829-35. doi: 10.1093/jac/47.6.829.
3
Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.使用载有利福平的缓释微球与异烟肼口服给药联合治疗结核病。
Antimicrob Agents Chemother. 2001 Jun;45(6):1637-44. doi: 10.1128/AAC.45.6.1637-1644.2001.
4
Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis.作为一种治疗结核病的方法，从单次注射剂量的聚（DL-丙交酯-共-乙交酯）微粒中持续释放异烟肼。
Int J Antimicrob Agents. 2001 Feb;17(2):115-22. doi: 10.1016/s0924-8579(00)00330-7.
5
Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.聚（DL-丙交酯-共-乙交酯）包裹的抗结核药物对小鼠诱导的结核分枝杆菌感染的治疗效果。
Antimicrob Agents Chemother. 2001 Jan;45(1):363-6. doi: 10.1128/AAC.45.1.363-366.2001.
6
Large porous particles for pulmonary drug delivery.用于肺部药物递送的大孔颗粒。
Science. 1997 Jun 20;276(5320):1868-71. doi: 10.1126/science.276.5320.1868.
7
Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer.在单次植入可生物降解聚合物后，兔子体内异烟肼治疗活性水平的长期维持。
Tuber Lung Dis. 1994 Oct;75(5):361-5. doi: 10.1016/0962-8479(94)90082-5.
8
Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids.
Indian J Med Res. 1980 Jan;71:129-34.
9
Fluorometric determination of isonicotinic acid hydrazide in serum.血清中异烟肼的荧光测定法。
J Lab Clin Med. 1967 Aug;70(2):355-60.
10
Therapeutic efficacy of liposome-entrapped rifampin against Mycobacterium avium complex infection induced in mice.脂质体包裹的利福平对小鼠鸟分枝杆菌复合群感染的治疗效果。
Antimicrob Agents Chemother. 1989 Apr;33(4):429-33. doi: 10.1128/AAC.33.4.429.